Int J Clin Rheumatol. 2010;5(4):407-413.

Objective The present study aimed to provide a comprehensive evaluation of the postmarketing safety of belimumab based on the Food and Drug Administration Adverse Event Reporting System (FAERS) ...

Benlysta binds and neutralises the B cell survival factor BAFF, while rituximab targets CD20, a protein found on the surface of B cells. The anti-CD20 mechanism could also lead to some competition ...

Preclinical studies using transgenic mice expressing human CD19 have shown that pre-B cells and their malignant counterparts, as well as pre-existing antibody-producing and autoantibody-producing ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

We will cover first clinical results of applying anti-CD19 and anti-B cell maturation antigen CAR T cells for B cell elimination ... anti-CD20 (Rituximab) or anti-BAFF (Belimumab) antibodies), T cells ...

Belimumab and atacicept target B-cell derived B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), respectively, which promote differentiation toward autoantibody-producing ...

It is notoriously hard to treat effectively. Saphnelo will compete in the market most closely with GlaxoSmithKline's BLyS inhibitor Benlysta (belimumab), which has been available in the EU to ...